155 related articles for article (PubMed ID: 8634781)
1. Contribution of p53 gene alterations to development of metastatic forms of follicular thyroid carcinoma.
Sápi Z; Lukács G; Sztán M; Papp J; Oláh E
Diagn Mol Pathol; 1995 Dec; 4(4):256-60. PubMed ID: 8634781
[TBL] [Abstract][Full Text] [Related]
2. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
[TBL] [Abstract][Full Text] [Related]
3. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.
Donghi R; Longoni A; Pilotti S; Michieli P; Della Porta G; Pierotti MA
J Clin Invest; 1993 Apr; 91(4):1753-60. PubMed ID: 8473515
[TBL] [Abstract][Full Text] [Related]
4. Molecular characterization of well-differentiated human thyroid carcinomas by cDNA arrays.
Zhao J; Leonard C; Brunner E; Gemsenjäger E; Heitz PU; Odermatt B
Int J Oncol; 2006 Nov; 29(5):1041-51. PubMed ID: 17016634
[TBL] [Abstract][Full Text] [Related]
5. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
6. Genetic mutations in thyroid carcinoma.
Taccaliti A; Boscaro M
Minerva Endocrinol; 2009 Mar; 34(1):11-28. PubMed ID: 19209125
[TBL] [Abstract][Full Text] [Related]
7. Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours.
Wright PA; Lemoine NR; Goretzki PE; Wyllie FS; Bond J; Hughes C; Röher HD; Williams ED; Wynford-Thomas D
Oncogene; 1991 Sep; 6(9):1693-7. PubMed ID: 1923534
[TBL] [Abstract][Full Text] [Related]
8. Infrequent CDKN2 mutation in human differentiated thyroid cancers.
Tung WS; Shevlin DW; Bartsch D; Norton JA; Wells SA; Goodfellow PJ
Mol Carcinog; 1996 Jan; 15(1):5-10. PubMed ID: 8561866
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications.
Chevillard S; Ugolin N; Vielh P; Ory K; Levalois C; Elliott D; Clayman GL; El-Naggar AK
Clin Cancer Res; 2004 Oct; 10(19):6586-97. PubMed ID: 15475448
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial DNA alterations in thyroid cancer.
Tong BC; Ha PK; Dhir K; Xing M; Westra WH; Sidransky D; Califano JA
J Surg Oncol; 2003 Mar; 82(3):170-3. PubMed ID: 12619060
[TBL] [Abstract][Full Text] [Related]
11. Reduced nm 23-H1 messenger RNA expression in metastatic lymph nodes from patients with papillary carcinoma of the thyroid.
Arai T; Watanabe M; Onodera M; Yamashita T; Masunaga A; Itoyama S; Itoh K; Sugawara I
Am J Pathol; 1993 Jun; 142(6):1938-44. PubMed ID: 8389529
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic significance of histologic vascular invasion in papillary and follicular thyroid carcinomas.
Furlan JC; Bedard YC; Rosen IB
J Am Coll Surg; 2004 Mar; 198(3):341-8. PubMed ID: 14992733
[TBL] [Abstract][Full Text] [Related]
13. The natural protein kinase C alpha mutant is present in human thyroid neoplasms.
Prévostel C; Alvaro V; de Boisvilliers F; Martin A; Jaffiol C; Joubert D
Oncogene; 1995 Aug; 11(4):669-74. PubMed ID: 7651730
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological roles of alterations of tumor suppressor gene p16 in papillary thyroid carcinoma.
Lam AK; Lo CY; Leung P; Lang BH; Chan WF; Luk JM
Ann Surg Oncol; 2007 May; 14(5):1772-9. PubMed ID: 17195959
[TBL] [Abstract][Full Text] [Related]
15. Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions.
Pavelić K; Dedivitis RA; Kapitanović S; Cacev T; Guirado CR; Danić D; Radosević S; Brkić K; Pegan B; Krizanac S; Kusić Z; Spaventi S; Bura M
Mutat Res; 2006 Jul; 599(1-2):45-57. PubMed ID: 16698048
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic significance of selected oncogene and suppressor gene expression in follicular thyroid carcinoma].
Lange D; Ferenc T; Niewiadomska H; Włoch J; Turska M; Burkacka J; Kula D; Lewiński A; Jarzab B
Wiad Lek; 2001; 54 Suppl 1():72-8. PubMed ID: 12182065
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial D-Loop instability in thyroid tumours is not a marker of malignancy.
Máximo V; Lima J; Soares P; Botelho T; Gomes L; Sobrinho-Simões M
Mitochondrion; 2005 Oct; 5(5):333-40. PubMed ID: 16183030
[TBL] [Abstract][Full Text] [Related]
18. Frizzled-1 is down-regulated in follicular thyroid tumours and modulates growth and invasiveness.
Ulivieri A; Lavra L; Dominici R; Giacomelli L; Brunetti E; Sciacca L; Trovato M; Barresi G; Foukakis T; Jia-Jing L; Larsson C; Bartolazzi A; Sciacchitano S
J Pathol; 2008 May; 215(1):87-96. PubMed ID: 18306168
[TBL] [Abstract][Full Text] [Related]
19. Molecular analysis of mutations in thyroid tumors with TGGE.
Simon D; Goretzki PE; Schäfer C; Gorelov V; Ebeling B; Röher HD
Exp Clin Endocrinol Diabetes; 1995; 103(5):275-9. PubMed ID: 8536054
[TBL] [Abstract][Full Text] [Related]
20. [Poorly differentiated carcinoma of the thyroid--immunohistochemical evaluation of p53 and p27 protein expression].
Wierzchowski W; Szybiński P; Nowak W; Nowak K; Szybiński Z; Buziak-Bereza M; Stachura J
Wiad Lek; 2001; 54 Suppl 1():79-87. PubMed ID: 12182066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
